Ultragenyx agrees to sell rare pediatric PRV for $210M
Ultragenyx entered into an agreement to sell a rare pediatric disease Priority Review Voucher for $210M, per a Dow Jones Newswires report.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.